Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 6/20 | 0.79 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.45 |
| ▸ | FEN1 | P39748 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180306 | 0.89 | HSD17B1 (1.00) | HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL6819778 | 0.87 | HSD17B1 (0.59) | HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL29818187 | 0.79 | MAP4K4 (0.57) | HSD17B1HSD17B2MAP4K4ALOX5APFEN1 | |
| SCHEMBL30186373 | 0.79 | HSD17B1 (0.79) | HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL2323103 | 0.79 | MAP4K4 (0.57) | HSD17B1HSD17B2MAP4K4ALOX5APFEN1 | |
| SCHEMBL16826157 | 0.79 | KDM1A (0.50) | HSD17B1HSD17B2KDM1AMETAP2MAP4K4 | |
| SCHEMBL5318865 | 0.79 | KDM1A (0.50) | HSD17B1HSD17B2KDM1AMAP4K4ATR | |
| SCHEMBL13019060 | 0.78 | HSD17B1 (0.56) | HSD17B1HSD17B2PIK3CGPIK3CAPIK3CB | |
| SCHEMBL6700757 | 0.77 | PIK3CG (0.47) | HSD17B1HSD17B2PIK3CGFYNKDM1A | |
| SCHEMBL934072 | 0.77 | FEN1 (0.62) | ADORA1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100457757-C | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2009-02-04 | — | — | CN | disclosed |
| CN-1640877-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| CN-1202108-C | Spiro compounds, processes and intermediates | BANYU PHARMA CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-6803372-B2 | SUCH AS CIS-N-(4-BENZOYLPHENYL)-4-HYDROXY-3'-OXOSPIRO (CYCLOHEXANE-1,1' (3'H)-ISOBENZOFURAN)-4-CARBOXAMIDE FOR USE AS NEUROPEPTIDE Y RECEPTOR ANTAGONIST FOR TREATMENT BULIMIA, OBESITY OR DIABETES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-12 | — | — | US | disclosed |
| US-6723847-B2 | 3-OXO-N-(5-PHENYL-2-PYRIMIDINYL)SPIRO(4-AZAISOBENZOFURAN-1 (3H),1'-CYCLOHEXANE)-4'-CARBOXAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030220499-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-11-27 | — | — | US | disclosed |
| US-6649624-B2 | Useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1204663-B1 | NOVEL SPIRO COMPOUNDS WITH NEUROPEPTIDE Y ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030055251-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | MSD K.K. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | NPY1R, GPR119, NPY2R | HSD17B1 1370/4885HSD17B2 1373/4885PIK3CG 4594/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | HSD17B1 264/4885HSD17B2 296/4885PIK3CG 4196/4885 |
| US-20030055251-A1 | Novel spiro compounds | NPY1R, GPR119, OPRK1 | HSD17B1 263/4885HSD17B2 320/4885PIK3CG 4256/4885 |
| US-20030220499-A1 | Novel spiro compounds | NPY1R, OPRK1, OPRM1 | HSD17B1 227/4885HSD17B2 252/4885PIK3CG 4311/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | HSD17B1 925/4885HSD17B2 927/4885PIK3CG 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.